NYKD — Nykode Therapeutics ASA Income Statement
0.000.00%
Last trade - 00:00- NOK771.96m
- -NOK394.62m
- $8.68m
Annual income statement for Nykode Therapeutics ASA, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 215 | 34 | 7.17 | 12.9 | 8.68 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 36.7 | 44.7 | 60.3 | 71 | 57 |
| Operating Profit | 178 | -10.8 | -53.2 | -58.1 | -48.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 181 | -11.1 | -51 | -44.1 | -45.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 150 | -9.41 | -42.7 | -35.2 | -38.8 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 150 | -9.41 | -42.7 | -35.2 | -38.8 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 150 | -9.41 | -42.7 | -35.2 | -38.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.514 | -0.026 | -0.142 | -0.113 | -0.12 |
| Dividends per Share |